IFNG and ovarian cancer: Transcriptomic analyses from the TRIO026 phase II clinical trial (NCT02900560) corroborated these findings, showing that azacitidine and pembrolizumab upregulated inflammatory and cytolytic genes GZMA and GZMH and enriched pathways like IFNγ response and NK cell-mediated cytotoxicity in platinum-resistant ovarian cancer.